Name | Number of supported studies | Average coverage | |
---|---|---|---|
mesothelial cell | 10 studies | 44% ± 17% | |
retinal rod cell | 5 studies | 33% ± 19% | |
basal cell | 5 studies | 24% ± 12% | |
fibroblast | 5 studies | 42% ± 27% | |
retinal pigment epithelial cell | 4 studies | 49% ± 15% | |
epithelial cell | 4 studies | 38% ± 32% | |
glomerular endothelial cell | 3 studies | 21% ± 2% | |
extravillous trophoblast | 3 studies | 36% ± 9% | |
pancreatic ductal cell | 3 studies | 56% ± 6% | |
endothelial cell | 3 studies | 38% ± 29% | |
secretory cell | 3 studies | 36% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 2504.42 | 180 / 180 | 73% | 37.60 | 313 / 430 |
kidney | 83% | 726.79 | 74 / 89 | 78% | 196.94 | 703 / 901 |
adrenal gland | 99% | 2177.19 | 255 / 258 | 61% | 147.62 | 140 / 230 |
pancreas | 89% | 739.48 | 293 / 328 | 68% | 27.02 | 121 / 178 |
lung | 76% | 690.94 | 437 / 578 | 47% | 127.08 | 546 / 1155 |
breast | 81% | 775.27 | 374 / 459 | 30% | 25.13 | 339 / 1118 |
uterus | 63% | 258.02 | 107 / 170 | 39% | 31.65 | 180 / 459 |
bladder | 67% | 439.90 | 14 / 21 | 33% | 37.23 | 168 / 504 |
ureter | 0% | 0 | 0 / 0 | 100% | 9.24 | 1 / 1 |
blood vessel | 93% | 720.02 | 1237 / 1335 | 0% | 0 | 0 / 0 |
adipose | 86% | 2138.01 | 1032 / 1204 | 0% | 0 | 0 / 0 |
prostate | 43% | 311.38 | 106 / 245 | 25% | 5.78 | 123 / 502 |
skin | 29% | 4820.46 | 523 / 1809 | 35% | 37.61 | 167 / 472 |
stomach | 43% | 253.36 | 153 / 359 | 14% | 3.60 | 39 / 286 |
heart | 55% | 274.17 | 473 / 861 | 0% | 0 | 0 / 0 |
intestine | 34% | 151.65 | 329 / 966 | 15% | 11.72 | 80 / 527 |
liver | 38% | 154.54 | 86 / 226 | 10% | 15.30 | 41 / 406 |
eye | 0% | 0 | 0 / 0 | 48% | 45.23 | 38 / 80 |
esophagus | 18% | 72.90 | 257 / 1445 | 16% | 8.24 | 30 / 183 |
lymph node | 0% | 0 | 0 / 0 | 28% | 17.22 | 8 / 29 |
thymus | 13% | 30.17 | 85 / 653 | 12% | 3.42 | 70 / 605 |
brain | 7% | 38.06 | 179 / 2642 | 7% | 1.91 | 46 / 705 |
peripheral blood | 12% | 50.04 | 114 / 929 | 0% | 0 | 0 / 0 |
muscle | 12% | 26.74 | 96 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 11% | 7.71 | 5 / 45 |
spleen | 7% | 13.06 | 16 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007596 | Biological process | blood coagulation |
GO_0071498 | Biological process | cellular response to fluid shear stress |
GO_0005615 | Cellular component | extracellular space |
GO_0031012 | Cellular component | extracellular matrix |
GO_0005201 | Molecular function | extracellular matrix structural constituent |
GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
Gene name | TFPI2 |
Protein name | Tissue factor pathway inhibitor 2 Tissue factor pathway inhibitor 2 (TFPI-2) (Placental protein 5) (PP5) Tissue factor pathway inhibitor TFPI2 variant |
Synonyms | hCG_19196 |
Description | FUNCTION: May play a role in the regulation of plasmin-mediated matrix remodeling. Inhibits trypsin, plasmin, factor VIIa/tissue factor and weakly factor Xa. Has no effect on thrombin. . |
Accessions | ENST00000222543.11 [P48307-1] ENST00000451238.1 A0A3B3IS67 A0A3B3IRW1 ENST00000650573.1 ENST00000647793.1 A0A3B3ISY1 P48307 A4ZVU7 ENST00000649913.1 H7C4A3 |